Study | CVC type | Study double-blinded? | Guidewire exchange permitted? | More than one study CVC permitted per patient? | Proportion of withdrawals or dropouts | Intention to treat analysis reported? |
---|---|---|---|---|---|---|
Goldschmidt et al. 1995 [10] | Silver vs standard | -- | no | yes | 12.4% | no |
Bach et al. 1996 [11] | CHSS vs. standard | -- | no | no | -- | no |
Ciresi et al. 1996 [12] | CHSS vs. standard | -- | yes | yes | 5.4% | no |
van Heerden et al. 1996 [13] | CHSS vs. standard | -- | no | no | 11.5% | no |
Maki et al. 1997 [5] | CHSS vs. standard | yes | yes | yes | 8.8% | no |
Heard et al. 1998 [7] | CHSS vs. standard | -- | yes | yes | 15.6% | no |
Bach et al 1999 [14] | Silver vs standard | -- | yes | no | 13% | no |
Collin et al. 1999 [15] | CHSS vs. standard | -- | yes | yes | 2.1% | no |
Hannan et al. 1999 [16] | CHSS vs. standard | no | no | yes | -- | no |
Marik et al. 1999 [17] | CHSS vs. standard and MR vs. standard | no | no | no | 5.8% | no |
Sheng et al. 2000 [18] | CHSS vs. standard | yes | no | yes | -- | no |
Jaeger et al. 2001 [19] | Benzalkonium chloride vs. standard | no | no | no | -- | no |
Corral et al. 2003 [20] | Silver vs standard | no | yes | yes | 19.8% | no |
Brun-Buisson et al. 2004 [21] | CHSS vs standard | yes | yes | yes | 8.6% | no |
Leon et al. 2004 [22] | MR vs. standard | no | no | no | 21.1% | yes |
Yucel et al. 2004 [23] | Miconazole-rifampicin vs. standard | no | no | no | 29.4% | no |
Dunser et al. 2005 [24] | Silver vs standard | no | no | no | -- | no |
Rupp et al. 2005 [8] | CHSS vs. standard | yes | yes | no | 9.4% | yes |
Osma et al. 2006 [25] | CHSS vs. standard | -- | no | no | 0% | yes |
Kalfon et al. 2007 [26] | Silver vs. standard | no | no | yes | 19.2% | no |
Raad et al.1997 [9] | MR vs. standard | no | no | yes | 10.7% | no |